ArticleToxicology in vitro : an international journal published in association with BIBRA2026
Metabolic stability and effects of microsomal enzymes on the activity of the sonic hedgehog pathway inhibitor piperonyl butoxide.
Article in Toxicology in vitro : an international journal published in association with BIBRA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The pesticide synergist piperonyl butoxide (PBO) is a methylenedioxy compound used in many pesticide formulations. Previous studies identified PBO as an inhibitor of the Sonic hedgehog (Shh) signaling pathway and linked prenatal PBO exposure to adverse developmental outcomes. Mixed-function oxidases have been proposed to metabolize PBO, but the specific enzymes involved in its depletion have not been identified. Here we examined the metabolic stability of PBO in the presence of human liver microsomes and the involvement of the CYP-450 (CYPs) and FMO enzyme families on the in vitro depletion of PBO. We found that PBO is readily depleted by microsomal enzymes in the presence of NADPH. The CYP inhibitor SKF-525 A significantly decreased PBO depletion, while the FMO inhibitor methimazole did not. We then examined the depletion capacity of individual CYPs, focusing on isoforms with common human polymorphisms. CYP2C19, CYP2C9, and CYP3A4 exhibited the greatest PBO depletion capacity, while CYP1A2 and CYP2D6 demonstrated moderate capacity. Finally, the effect of microsomal activity on the antagonist activity of PBO against the Sonic hedgehog (Shh) pathway was assessed. Microsomal depletion reduced but did not eliminate the antagonistic activity of PBO on Shh pathway signaling activity. Collectively, these findings suggest a major role for mixed-function oxidases in PBO depletion and indicate the possible involvement of specific CYP isoforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.